Anticardiolipin Antibodies in Rheumatoid Arthritis

Keane, A.; Woods, R. J.; Dowding, V. M.; Roden, Denise A.; Barry, Chris

doi:10.1093/rheumatology/26.5.346

Cited by 49 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anticaridiolipin antibodies were present in a larger proportion of RF-positive than RF-negative patients in one study [34], but there was no relationship between them in others [19,35].…”

Section: Association Between Presence Of Acl and Disease Activity Ramentioning

confidence: 81%

“…In 1987 Keane et al [34] reported significantly higher proportion of males, extra-articular manifestations of RA and medial levels of C-reactive protein (CRP) among aCL-positive patients than in the aCL-negative group of RA patients. However, no significant difference was found between two groups with respect to duration, age of onset or functional class of the disease, or the presence or absence of radiologically confirmed erosive joint disease.…”

Section: Association Between Presence Of Acl and Disease Activity Ramentioning

confidence: 99%

See 1 more Smart Citation

The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis

Olech

Merrill²

2006

Curr Rheumatol Rep

View full text Add to dashboard Cite

Published data were reviewed to evaluate the occurrence of antiphospholipid antibodies (aPL) in rheumatoid arthritis (RA) patients and to investigate their clinical relevance in this population. The mean prevalence was calculated at 28% and the median was 22%. Few studies have found a relationship between aPL antibodies and thrombosis, particularly in combination with other risk factors. Conflicting results have been reported on the association of anticardiolipin (aCL) antibody positivity and neurologic symptoms, Reynaud's phenomenon, disease activity, radiographic erosions, extra-articular RA manifestations, rheumatoid factor, and atherosclerosis. Some studies, however, suggest that there is a correlation present between those antibodies and C-reactive protein levels, rheumatoid nodules, and antinuclear antibodies. TNF-alpha blocking agents may cause an induction of aCL antibodies, but it seems like they do not cause any clinical features related to the antiphospholipid syndrome. Higher 17beta-estradiol levels were observed in aCL antibody-positive RA patients than in aCL antibody-negative patients and especially in premenopausal women, which may predispose to a more efficient immune response.

show abstract

“…Anticaridiolipin antibodies were present in a larger proportion of RF-positive than RF-negative patients in one study [34], but there was no relationship between them in others [19,35].…”

Section: Association Between Presence Of Acl and Disease Activity Ramentioning

confidence: 81%

Section: Association Between Presence Of Acl and Disease Activity Ramentioning

confidence: 99%

The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis

Olech

Merrill²

2006

Curr Rheumatol Rep

View full text Add to dashboard Cite

show abstract

“…It has since become clear that aCL antibodies may be demonstrable in a variety of conditions that include other "autoimmune" diseases (23)(24)(25)(26)(27)(28)(29) and infections, particularly viral and spirochetal infections (30). They may also be induced by certain drugs such as chlorpromazine and procainamide (31)(32)(33).…”

Section: Resultsmentioning

confidence: 99%

Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.

Blank

Cohen

Toder

et al. 1991

Proc. Natl. Acad. Sci. U.S.A.

439

222

View full text Add to dashboard Cite

The primary anti-phospholipid syndrome is characterized by recurrent venous and arterial thromboembolic phenomena, recurrent fetal loss, thrombocytopenia, and serological evidence of anti-cardiolipin (aCL) antibodies or/and the presence of lupus anticoagulant (prolonged activated partial thromboplastin time). The exact role of aCL antibodies in pathogenesis is not clear and the mechanism by which the antibodies may induce the various manifestations is unknown. In the current study we evaluated the effect of passive transfer of aCL antibodies (to the tail vein of naive mice) on fecundity, fetal loss (fetal resorption), and the weight of embryos and placentae. Two types of aCL antibodies were employed: (t0 mouse monoclonal aCL antibodies derived from a BALB/c mouse in which experimental systemic lupus erythematosus was induced by a pathogenic idiotype (idiotype 16/6) of anti-DNA antibodies and (ii) polyclonal IgG and IgM aCL antibodies derived from serum of a patient with primary anti-phospholipid syndrome. After infusion of either antibody (10 jug per mouse) we could demonstrate lower fecundity rate, increased resorption index of embryos (equivalent to recurrent fetal loss), lower number ofembryos per pregnancy, and lower mean weights of embryos and placentae in comparison to mice infused with appropriate control immunoglobulins. We conclude that the aCL antibodies may have direct effects on fecundity and on the outcome of pregnancy.

show abstract

“…Similar results haven been found in RA patients in which the prevalence of aCL antibodies has been estimated at about 30%; nevertheless, thrombotic manifestation in these patients is a rare clinical condition. 36 Although some researchers have postulate d that RF could be a protecting factor against thrombotic phenomena, there is no strong evidence to support the hypothesis. 37 However, it is important to know the mechanism by which the aCL antibodies are generated in those patients and further investigation s are needed.…”

Section: Discussionmentioning

confidence: 99%

Clinical and immunogenetic characterization of Mexican patients with ‘Rhupus’

Simón

Granados²,

Cabiedes³

et al. 2002

Lupus

View full text Add to dashboard Cite

The coexistence of systemic lupus erythematosus and rheumatoid arthritis (rhupus), is a rare clinical condition. To date, 50 cases of rhupus have been described worldwide; however, the lack of clinical criteria for this rheumatic condition has created confusion in the characterization of this disorder. Nevertheless, in this paper we describe a comprehensive clinical and serological characterization of a cohort of 22 Mexican patients with rhupus, supported by generic HLA-DR phenotyping. We found that rhupus patients have a special clinical behavior. In this setting, the signs and symptoms of rheumatoid arthritis prevail, little organic damage associated with systemic lupus erythematosus (SLE) exists and none of the cases present thrombosis or morbidity during pregnancy in spite of presenting a high frequency of anticardiolipin antibodies. We also found an increased frequency of HLA-DR1 and HLA-DR2 alleles compared to healthy ethnically matched controls, systemic lupus erythematosus and rheumatoid arthritis patients.

show abstract

Anticardiolipin Antibodies in Rheumatoid Arthritis

Cited by 49 publications

References 0 publications

The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis

The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis

Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.

Clinical and immunogenetic characterization of Mexican patients with ‘Rhupus’

Contact Info

Product

Resources

About